Open Access Open Access  Restricted Access Subscription Access

Medication Risk Management: A Subjective Review of Present Scenario

AK Mohiuddin


Historically, the FDA has deciphered the prerequisite that a medication must be "sheltered" to imply that the advantages of a medication exceed its dangers. The assurance was made on an "all out" premise, where the totality of dangers was weighted against the totality of advantages when considered for the reasons laid out in the medication item's marking. On the off chance that a medication did not meet this rule, it was not endorsed or its name was revamped to limit the conditions for use. This rationale was endemic in the FDA for the majority of the twentieth century. All things considered, two to four medications over every 5-year time frame were pulled back from the commercial center after post-promoting observation information revealed new dangers. Essentially, now and again, the FDA would require some exceptional "instrument" or intercession to enhance an item's wellbeing profile. Damage related with prescription remains the second most basic kind of occurrence in medical clinics, as announced by the Clinical Excellence Commission. Wellbeing administrations effectively audit drug security. Most by far of medicine blunders result in no damage. Minor damage may result, for instance, in a patient requiring an expanded dimension of observing. Regardless of whether occurrences result in minor damage, directors staff still consider any blunders important, inspecting the activities around the episode and making upgrades accordingly. FDA's new ideas for hazard the board add up to a "social move" in the rationale of medication endorsement and the FDA's job. The key occasions that prompted this change can be followed to a progression of reports that featured the requirement for enhanced restorative wellbeing. In 1999, the IOM discharged a report entitled, "To Err is Human." This report investigated the nature and reason for medicine blunders, evaluating that up to 98,000 individuals kicked the bucket every year because of these mistakes. In their evaluation the IOM included both antagonistic medication responses and human mistakes in medication organization. The report caught the consideration of news columnists and the legislature. Features declared alert at the bigger number of fatalities brought about by therapeutic blunders. Thus, there was an administration wide activity begun to create strategies and organization systems to lessen restorative mistakes. Articulations made by FDA authorities in regards to a portion of these withdrawals recommended that the FDA never again trusted that latent oversight and re-naming medications with new admonitions was adequate. Besides, the FDA never again trusted that it was adequate to distinguish safe states of utilization in the name and that human services experts and patients needed to consent to supported bearings of utilization for the medication to stay available.


Full Text:



Aronson JK. Risk perception in drug therapy. Br J Clin Pharmacol. 2006; 62(2):135-7.

Risk Perception: Theories, Strategies, and Next Step by National Safety Council 2014. Available from:

Paek H, Hove T. Risk Perceptions and Risk Characteristics. Oxford Research Encyclopedia of Communication March 2017. DOI: 10.1093/acrefore/9780190228613.013.283

Ferrer R, Klein WM. Risk perceptions and health behavior. Curr Opin Psychol. 2015; 5:85-89. Available from:

National Research Council (US) Committee on Occupational Health and Safety in the Care and Use of Nonhuman Primates. Occupational Health and Safety in the Care and Use of Nonhuman Primates. Washington (DC): National Academies Press (US); 2003. 5, Risk Assessment: Evaluating Risks to Human Health and Safety. Available from:

The New England Journal of Medicine Web. What Is Risk Management in Healthcare? April 25, 2018

The University of Scranton, Pennsylvania Web. The Purpose of Risk Management in Healthcare. Available From:

Taha H, Raji SJ, Khallaf A, et al. Improving Catheter Associated Urinary Tract Infection Rates in the Medical Units. BMJ Qual Improv Rep. 2017;6(1):u209593.w7966. Published 2017 Apr 6. doi:10.1136/bmjquality.u209593.w7966

Meddings J, Rogers MA, Krein SL, Fakih MG, Olmsted RN, Saint S. Reducing unnecessary urinary catheter use and other strategies to prevent catheter-associated urinary tract infection: an integrative review. BMJ Qual Saf. 2013; 23(4):277-89.

Alam AY (2016). Steps in the Process of Risk Management in Healthcare. J Epid Prev Med 2(2): 118.

Moskowitz D. The Importance of Healthcare Risk Management. Investopedia Web. Mar 28, 2018

Origami Risk Web. Industry Spotlight: Healthcare Risk Management. December 10, 2018

Curtin F, Schulz P. Assessing the benefit: risk ratio of a drug--randomized and naturalistic evidence. Dialogues Clin Neurosci. 2011; 13(2):183-90.

Edwards R, Wiholm BE, Martinez C. Concepts in risk-benefit assessment. A simple merit analysis of a medicine? Drug Saf. 1996 Jul;15(1):1-7. PubMed PMID: 8862960.

Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs; Board on Population Health and Public Health Practice; Institute of Medicine. Ethical and Scientific Issues in Studying the Safety of Approved Drugs. Washington (DC): National Academies Press (US); 2012 May 1. 2, Incorporating Benefit and Risk Assessment and Benefit–Risk Management into Food and Drug Administration Decision-Making.

European Medicines Agency Benefit-Risk methodology project EMA/213482/2010, pp 1-3

Web European Medicines Agency. ENCePP: Where are we and where are we going? Annual PC WP & HCP WG Joint meeting London, 16 June 2011. Available from:

Guo JJ, Pandey S, Doyle J, Bian B, Lis Y, Raisch DW. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group. Value Health. 2010 Aug; 13(5):657-66. doi: 10.1111/j.1524-4733.2010.00725.x. Epub 2010 Apr 15. Review. PubMed PMID: 20412543.

Adibi H, Khalesi N, Ravaghi H, Jafari M, Jeddian AR. Development of an effective risk management system in a teaching hospital. J Diabetes Metab Disord. 2012;11(1):15. Published 2012 Sep 21. doi:10.1186/2251-6581-11-15

Van Steenkiste B, Grol R, van der Weijden T. Systematic review of implementation strategies for risk tables in the prevention of cardiovascular diseases. Vasc Health Risk Manag. 2008; 4(3):535-45.

Eccles M, Grimshaw J, Campbell M, et al Research designs for studies evaluating the effectiveness of change and improvement strategies BMJ Quality & Safety 2003;12:47-52.

Mayall SJ. Banerjee AS. Chapter 6. Overview of risk management around the world. In: Stephen J. Mayall Anjan Swapu Banerjee. Therapeutic Risk Management of Medicines. Publisher: Woodhead Publishing; 1 edition (March 27, 2014)

ASHRM 2019-2021 Strategic Plan. Available From:

American Society for Health Care Risk Management (ASHRM) Web. 2019 ASHRM Annual Conference.

Etges APBDS, Grenon V, Lu M, Cardoso RB, de Souza JS, Kliemann Neto FJ, Felix EA. Development of an enterprise risk inventory for healthcare. BMC Health Serv Res. 2018 Jul 24; 18(1):578. doi: 10.1186/s12913-018-3400-7. PubMed PMID: 30041651; PubMed Central PMCID: PMC6057062.

P Stevens, J Noble; ISQUA17-2143 Managing Top Risks In Healthcare Through A Shared Integrated (Enterprise) Risk Management Approach, International Journal for Quality in Health Care, Volume 29, Issue suppl_1, 1 September 2017, Pages 19–20,

Borovoy L. 7 steps to Integrated Risk Management Web Healthcare Insurance Reciprocal of Canada (HIROC). Monday, January 7, 2019

Web United States Agency for International Development (USAID). Developing a Risk Management Plan. Available from:

Farokhzadian J, Nayeri ND, Borhani F. BMC Health Serv Res. 2018; 18: 654. The long way ahead to achieve an effective patient safety culture: challenges perceived by nurses

doi: 10.1186/s12913-018-3467-1 PMID: 30134980

Web European Medicines Agency (EMA). Guideline on key aspects for the use of pharmacogenomic s in the pharmacovigilance of medicinal products. Available from:

Fischer F, Lange K, Klose K, Greiner W, Kraemer A. Barriers and Strategies in Guideline Implementation-A Scoping Review. Healthcare (Basel, Switzerland). 2016; 4(3): 36.

Beyene K, Aspden T, Sheridan J. Prescription medicine sharing: exploring patients’ beliefs and experiences. J Pharm Policy Pract. 2016; 9(1):23. doi: 10.1186/s40545-016-0075-5.

Callen JL, Westbrook JI, Georgiou A, et al. Failure to follow-up test results for ambulatory patients: a systematic review. J Gen Intern Med 2012;27:1334–48. 10.1007/s11606-011-1949-5

Callen J, Georgiou A, Li J, Westbrook IJ. The Impact for Patient Outcomes of Failure to Follow Up on Test Results. How Can We Do Better? EJIFCC. 2015 Jan; 26(1): 38–46. Published online 2015 Jan 27. PMID: 27683480

King A, Hoppe RB. “Best practice” for patient-centered communication: a narrative review. J Grad Med Educ. 2013; 5:385–393.

Health Quality Ontario. Prevention of falls and fall-related injuries in community-dwelling seniors: an evidence-based analysis. 2008;8(2):1–78

Evans RS. Electronic health records: then, now, and in the future. Yearb Med Inform. 2016; 20:S48–S61.

Baldo, P., Francescon, S. & Fornasier, G. Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology. Int J Clin Pharm (2018) 40: 748. PMCID: PMC6132975

PMID: 30094557

Radecka A, Loughlin L, Foy M, de Ferraz Guimaraes MV, Sarinic VM, Di Giusti MD, Lesicar M, Straus S, Montero D, Pallos J, Ivanovic J, Raine J. Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action. Drug Saf. 2018 Dec; 41(12):1285-1302. doi: 10.1007/s40264-018-0708-5. PubMed PMID: 30128638; PubMed Central PMCID: PMC6223699.

Hans M, Gupta SK. Comparative evaluation of pharmacovigilance regulation of the United States, United Kingdom, Canada, India and the need for global harmonized practices. Perspect Clin Res. 2018 Oct-Dec;9(4):170-174. doi: 10.4103/picr.PICR_89_17. Review. PubMed PMID: 30319947; PubMed Central PMCID: PMC6176689.

Linger M, Martin J. Pharmacovigilance and expedited drug approvals. Aust Prescr 2018; 41:50-3. 10.18773/austprescr.2018.010

Grampp G, Felix T. Pharmacovigilance Considerations for Biosimilars in the USA. BioDrugs. 2015 Oct; 29(5):309-21. doi: 10.1007/s40259-015-0137-2. PubMed PMID: 26419971; PubMed Central PMCID: PMC4626527.

Web TGA (Australian Government Department of Health Therapeutic Godds Administration), 12 December 2017. Risk management plans for medicines and biologicals. Available From:

Vora P, Artime E, Soriano-Gabarró M, Qizilbash N, Singh V, Asiimwe A. A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European Union electronic Register of Post-Authorization Studies. Pharmacoepidemiol Drug Saf. 2018 Jul; 27(7):695-706. doi: 10.1002/pds.4434. Epub 2018 Apr 16. Review. PubMed PMID: 29663572; PubMed Central PMCID: PMC6055865.

Morrato EH, Smith MY. Integrating risk minimization planning throughout the clinical development and commercialization lifecycle: an opinion on how drug development could be improved. Ther Clin Risk Manag. 2015 Feb 26; 11:339-48. doi: 10.2147/TCRM.S78202. eCollection 2015. PubMed PMID: 25750537; PubMed Central PMCID: PMC4348129.

The Australian Council on Healthcare Standards (ACHS), Risk Management and Quality Improvement Handbook. Sydney Australia; ACHS; 2013

Available From:

Silver SA, Harel Z, McQuillan R, Weizman AV, Thomas A, Chertow GM, Nesrallah G, Bell CM, Chan CT. How to Begin a Quality Improvement Project. Clin J Am Soc Nephrol. 2016 May 6; 11(5):893-900. doi: 10.2215/CJN.11491015. Epub 2016 Mar 25. PubMed PMID: 27016497; PubMed Central PMCID: PMC4858490.

Australian Commission on Safety and Quality in Health Care, National Safety and Quality Health Service Standards (September 2012). Sydney. ACSQHC, 2012. Available From:

Web Agency for Healthcare Research and Quality. National Guideline Clearinghouse. Inclusion criteria. Available From:

Institute of Medicine (US) Committee on the Work Environment for Nurses and Patient Safety; Page A, editor. Keeping Patients Safe: Transforming the Work Environment of Nurses. Washington (DC): National Academies Press (US); 2004. 4, Transformational Leadership and Evidence-Based Management. Available from:

Rosenfeld RM, Shiffman RN. Clinical practice guideline development manual: a quality-driven approach for translating evidence into action. Otolaryngol Head Neck Surg. 2009 Jun; 140(6 Suppl 1):S1-43. doi: 10.1016/j.otohns.2009.04.015. PubMed PMID: 19464525; PubMed Central PMCID: PMC2851142.

Web Health Providers Service Organization. Integrating Risk Management and Quality Improvement. Available From:


  • There are currently no refbacks.